Changes of VEGF-C,VEGF-D and VEGF-R-3 expression by NM-3 of orthotopic implantated tumor from human gastric cancer(SGC7901) cell line in BALB/C nude mice

Objective:To evaluate the inhibition effect of NM-3 on VEGF-C,VEGF-D and VEGF-R-3 expression of orthotopic implantated tumor from human gastric cancer(SGC7901) cell line in BALB/C nude mice.Methods:Human gastric cancer tissue originated from SGC-7901 cell line was orthotopicly implantated into the stomach of nude mice.After one week of normally feeding,28 Balb/C nude mice were divided into 4 groups (7 nude mice in each group) randomly:control group,NM-3 treatment group (5mg/kg),carboplatin treatment group(10mg/kg),and NM-3 combined with carboplatin group(NM-3,5mg/kg and carboplatin,10mg/kg).The mice were administered i.p.respectively in the related groups twice a week for 8 weeks.Then the mice were sacrificed and tested for VEGF-C,VEGF-D and VEGF-R-3 by immunohistochemistry staining method.Results:VEGF-C of carboplatin group(1647.83±501.70),NM-3 group(2106.01±437.11) and combinative group(1825.61±277.24) was significantly lower than VEGF-C control group(2962.84±519.77)(P0.05).There was no significant difference among treatment groups.VEGF-D of NM-3 group(1032.25±460.44) and combined treatment group(1009.08±370.13) was significantly lower than control group(1882.15±359.38) and carboplatin group(1854.00±322.07)(P0.05).There was no significant difference between carboplatin group and control group.VEGF-R-3 of NM-3 group(1222.05±470.80) and combined group(1103.34±265.94) was significantly lower than control group(2123.05±117.99)(P0.05),VEGF-R-3 of carboplatin group(1668.30±256.34) was lower than control group,but there was no significant difference between them,and among all treatment groups.Conclusion:NM-3 can inhibit lymphangiogenesis of gastric cancer.Combined therapy of NM-3 and carboplatin shows more remarkable inhibition on the growth of gastric cancer.